The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
 
Yasmin Karimi
Consulting or Advisory Role - Abbvie; ADC Therapeutics
Research Funding - Abbvie; AstraZeneca; Loxo/Lilly; Merck; Roche/Genentech; Xencor
Travel, Accommodations, Expenses - Roche/Genentech
 
Pau Abrisqueta
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Janssen
Speakers' Bureau - Abbvie; AstraZeneca; Bristol-Myers Squibb; Janssen
 
Sven de Vos
No Relationships to Disclose
 
Marcel Nijland
Consulting or Advisory Role - Abbvie/Genentech (Inst)
Research Funding - Takeda (Inst)
 
Fritz Offner
No Relationships to Disclose
 
Kojo Osei-Bonsu
Employment - Abbvie
 
Ali Rana
Employment - Genmab
 
Kimberly G. Archer
Employment - Genmab
 
Yaou Song
Employment - Genmab
 
Raul Cordoba
Consulting or Advisory Role - Celgene/Bristol-Myers Squibb; Incyte; Janssen; Kite/Gilead; Kyowa-Kirin; Takeda
Speakers' Bureau - Abbvie; AstraZeneca; Roche
Research Funding - Pfizer
Travel, Accommodations, Expenses - Abbvie; Janssen; Roche
 
Lorenzo Falchi
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; EvolveImmune Therapeutics; Genmab; Ipsen; Roche/Genentech; Seagen
Research Funding - Abbvie; BeiGene; Genentech; Genmab; Innate Pharma; Roche
Travel, Accommodations, Expenses - Abbvie; Genmab